Immunisation with the glycolytic enzyme enolase confers effective protection against Candida albicans infection in mice

Vaccine

Volumn 29, Issue 33, 2011, Pages 5526-5533

  Li, Wen qing ^a   Hu, Xu chu ^b,c   Zhang, Xiaohuan ^a   Ge, Yanping ^a   Zhao, Sainan ^a   Hu, Yan ^a   Ashman, Robert B ^d  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antibody; Candida albicans; Candidiasis; Cytokine; Enolase; Vaccine

Indexed keywords

CYTOKINE; GLYCOLYTIC ENZYME; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 8; RECOMBINANT ENOLASE; RECOMBINANT ENZYME; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELL INFILTRATION; CELL WALL; DISEASE SEVERITY; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; IMMUNITY; IMMUNIZATION; MOLECULAR CLONING; MOUSE; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; OPSONIZATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ANIMAL STRUCTURES; ANIMALS; ANTIBODIES, FUNGAL; ANTIGENS, FUNGAL; CANDIDA ALBICANS; CANDIDIASIS; COLONY COUNT, MICROBIAL; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FUNGAL VACCINES; HISTOCYTOCHEMISTRY; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; OPSONIN PROTEINS; PHOSPHOPYRUVATE HYDRATASE; RODENT DISEASES; VACCINATION; VACCINES, SYNTHETIC;

EID: 79960371037     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.030     Document Type: Article

References (43)

1. Schaberg D.R., Culver D.H., Gaynes R.P. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991, 91(3B):72S-75S.
2. Spellberg B.J., Filler S.G., Edwards J.E. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006, 42(2):244-251.
3. Wong L.P., Woo P.C., Wu A.Y., Yuen K.Y. DNA immunization using a secreted cell wall antigen Mp1p is protective against Penicillium marneffei infection. Vaccine 2002, 20(23-24):2878-2886.
4. Cenci E., Romani L., Vecchiarelli A., Puccetti P., Bistoni F. Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice. Infect Immun 1989, 57(11):3581-3587.
5. Fernandez-Arenas E., Molero G., Nombela C., Diez-Orejas R., Gil C. Low virulent strains of Candida albicans: unravelling the antigens for a future vaccine. Proteomics 2004, 4(10):3007-3020.
6. Torosantucci A., Bromuro C., Chiani P., De Bernardis F., Berti F., Galli C., et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005, 202(5):597-606.
7. Poulain D., Slomianny C., Jouault T., Gomez J.M., Trinel P.A. Contribution of phospholipomannan to the surface expression of beta-1,2-oligomannosides in Candida albicans and its presence in cell wall extracts. Infect Immun 2002, 70(8):4323-4328.
8. Hu Y., Farah C.S., Ashman R.B. Isolates of Candida albicans that differ in virulence for mice elicit strain-specific antibody-mediated protective responses. Microbes Infect 2006, 8(3):612-620.
9. Franklyn K.M., Warmington J.R., Ott A.K., Ashman R.B. An immunodominant antigen of Candida albicans shows homology to the enzyme enolase. Immunol Cell Biol 1990, 68(Pt 3):173-178.
10. Matthews R., Burnie J. Cloning of a DNA sequence encoding a major fragment of the 47kilodalton stress protein homologue of Candida albicans. FEMS Microbiol Lett 1989, 51(1):25-30.
11. Hu Y. Murine immune responses to strains of Candida albicans. Ph.D. Thesis. University of Queensland, Brisbane, Australia; 2004:122.
12. Kustrzeba-Wojcicka I., Golczak M. Enolase from Candida albicans-purification and characterization. Comp Biochem Physiol B Biochem Mol Biol 2000, 126(1):109-120.
13. Angiolella L., Facchin M., Stringaro A., Maras B., Simonetti N., Cassone A. Identification of a glucan-associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics. J Infect Dis 1996, 173(3):684-690.
14. Angiolella L., Micocci M.M., D'Alessio S., Girolamo A., Maras B., Cassone A. Identification of major glucan-associated cell wall proteins of Candida albicans and their role in fluconazole resistance. Antimicrob Agents Chemother 2002, 46(6):1688-1694.
15. Eroles P., Sentandreu M., Elorza M.V., Sentandreu R. The highly immunogenic enolase and Hsp70p are adventitious Candida albicans cell wall proteins. Microbiology 1997, 143(Pt 2):313-320.
16. Sandini S., Melchionna R., Arancia S., Gomez M.J., La Valle R. Generation of a highly immunogenic recombinant enolase of the human opportunistic pathogen Candida albicans. Biotechnol Appl Biochem 1999, 29(Pt 3):223-227.
17. Lain A., Moragues M.D., Ruiz J.C., Mendoza J., Camacho A., Del Palacio A., et al. Evaluation of a novel enzyme-linked immunosorbent assay to detect immunoglobulin G antibody to enolase for serodiagnosis of invasive candidiasis. Clin Vaccine Immunol 2007, 14(3):318-319.
18. Pitarch A., Abian J., Carrascal M., Sanchez M., Nombela C., Gil C. Proteomics-based identification of novel Candida albicans antigens for diagnosis of systemic candidiasis in patients with underlying hematological malignancies. Proteomics 2004, 4(10):3084-3106.
19. Pitarch A., Jimenez A., Nombela C., Gil C. Decoding serological response to Candida cell wall immunome into novel diagnostic, prognostic, and therapeutic candidates for systemic candidiasis by proteomic and bioinformatic analyses. Mol Cell Proteomics 2006, 5(1):79-96.
20. Montagnoli C., Sandini S., Bacci A., Romani L., La Valle R. Immunogenicity and protective effect of recombinant enolase of Candida albicans in a murine model of systemic candidiasis. Med Mycol 2004, 42(4):319-324.
21. Hu Y. Murine immune responses to strains of Candida albicans. Ph.D. Thesis. University of Queensland, Brisbane, Australia; 2004:41.
22. Zhang S.M., Lv Z.Y., Zhou H.J., Yang L.L., Yu X., Wu Z.D., et al. Characterization of a profilin-like protein from Schistosoma japonicum, a potential new vaccine candidate. Parasitol Res 2008, 106(6):1367-1374.
23. Farah C.S., Hu Y., Riminton S., Ashman R.B. Distinct roles for interleukin-12p40 and tumour necrosis factor in resistance to oral candidiasis defined by gene-targeting. Oral Microbiol Immunol 2006, 21(4):252-255.
24. Farah C.S., Ashman R.B. Active and passive immunization against oral Candida albicans infection in a murine model. Oral Microbiol Immunol 2005, 20(6):376-381.
25. Cowland J.B., Borregaard N. Isolation of neutrophil precursors from bone marrow for biochemical and transcriptional analysis. J Immunol Methods 1999, 232(1-2):191-200.
26. Giudicelli J., Philip P.J., Delque P., Sudaka P. A single-step centrifugation method for separation of granulocytes and mononuclear cells from blood using discontinuous density gradient of Percoll. J Immunol Methods 1982, 54(1):43-46.
27. Fu Y., Luo G., Spellberg B.J., Edwards J.E., Ibrahim A.S. Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans. Eukaryot Cell 2008, 7(3):483-492.
28. Luo G., Ibrahim A.S., Spellberg B., Nobile C.J., Mitchell A.P., Fu Y. Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis 2010, 201(11):1718-1728.
29. Tuite A., Mullick A., Gros P. Genetic analysis of innate immunity in resistance to Candida albicans. Genes Immun 2004, 5(7):576-587.
30. Moragues M.D., Omaetxebarria M.J., Elguezabal N., Sevilla M.J., Conti S., Polonelli L., et al. A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect Immun 2003, 71(9):5273-5279.
31. Xin H., Cutler J.E. Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis. Infect Immun 2006, 74(7):4310-4321.
32. Marodi L., Forehand J.R., Johnston R.B. Mechanisms of host defense against Candida species. II. Biochemical basis for the killing of Candida by mononuclear phagocytes. J Immunol 1991, 146(8):2790-2794.
33. Pereira H.A., Hosking C.S. The role of complement and antibody in opsonization and intracellular killing of Candida albicans. Clin Exp Immunol 1984, 57(2):307-314.
34. Jensen J., Warner T., Balish E. The role of phagocytic cells in resistance to disseminated candidiasis in granulocytopenic mice. J Infect Dis 1994, 170(4):900-905.
35. Kagaya K., Fukazawa Y. Murine defense mechanism against Candida albicans infection. II. Opsonization, phagocytosis, and intracellular killing of C. albicans. Microbiol Immunol 1981, 25(8):807-818.
36. Romani L., Mencacci A., Cenci E., Puccetti P., Bistoni F. Neutrophils and the adaptive immune response to Candida albicans. Res Immunol 1996, 147(8-9):512-518.
37. Hu Y., Farah C.S., Ashman R.B. Effector function of leucocytes from susceptible and resistant mice against distinct isolates of Candida albicans. Immunol Cell Biol 2006, 84(5):455-460.
38. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004, 4(1):1-23.
39. Djeu J.Y., Matsushima K., Oppenheim J.J., Shiotsuki K., Blanchard D.K. Functional activation of human neutrophils by recombinant monocyte-derived neutrophil chemotactic factor/IL-8. J Immunol 1990, 144(6):2205-2210.
40. Ashman R.B., Farah C.S., Wanasaengsakul S., Hu Y., Pang G., Clancy R.L. Innate versus adaptive immunity in Candida albicans infection. Immunol Cell Biol 2004, 82(2):196-204.
41. Ashman R.B., Vijayan D., Wells C.A. IL-12 and related cytokines: function and regulatory implications in Candida albicans infection. Clin Dev Immunol 2011, 686597.
42. Moore K.W., O'Garra A., de Waal Malefyt R., Vieira P., Mosmann T.R. Interleukin-10. Annu Rev Immunol 1993, 11:165-190.
43. Vazquez-Torres A., Jones-Carson J., Wagner R.D., Warner T., Balish E. Early resistance of interleukin-10 knockout mice to acute systemic candidiasis. Infect Immun 1999, 67(2):670-674.